Cited by
Cited by
Oral selinexor–dexamethasone for triple-class refractory multiple myeloma
A Chari, DT Vogl, M Gavriatopoulou, AK Nooka, AJ Yee, CA Huff, ...
New England Journal of Medicine 381 (8), 727-738, 2019
Organ-specific manifestations of COVID-19 infection
M Gavriatopoulou, E Korompoki, D Fotiou, I Ntanasis-Stathopoulos, ...
Clinical and experimental medicine 20, 493-506, 2020
Emerging treatment strategies for COVID-19 infection
M Gavriatopoulou, I Ntanasis-Stathopoulos, E Korompoki, D Fotiou, ...
Clinical and experimental medicine 21, 167-179, 2021
Pathogenesis of bone disease in multiple myeloma: from bench to bedside
E Terpos, I Ntanasis-Stathopoulos, M Gavriatopoulou, MA Dimopoulos
Blood cancer journal 8 (1), 7, 2018
Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): a randomised, open-label …
S Grosicki, M Simonova, I Spicka, L Pour, I Kriachok, M Gavriatopoulou, ...
The Lancet 396 (10262), 1563-1573, 2020
Primary therapy of Waldenström macroglobulinemia (WM) with weekly bortezomib, low-dose dexamethasone, and rituximab (BDR): long-term results of a phase 2 study of the European …
MA Dimopoulos, R García-Sanz, M Gavriatopoulou, P Morel, ...
Blood, The Journal of the American Society of Hematology 122 (19), 3276-3282, 2013
Extensive bone marrow infiltration and abnormal free light chain ratio identifies patients with asymptomatic myeloma at high risk for progression to symptomatic disease
E Kastritis, E Terpos, L Moulopoulos, M Spyropoulou-Vlachou, ...
Leukemia 27 (4), 947-953, 2013
Epidemiology and organ specific sequelae of post-acute COVID19: a narrative review
E Korompoki, M Gavriatopoulou, RS Hicklen, I Ntanasis-Stathopoulos, ...
Journal of Infection 83 (1), 1-16, 2021
Oncology during the COVID‑19 pandemic: challenges, dilemmas and the psychosocial impact on cancer patients
K Tsamakis, M Gavriatopoulou, D Schizas, A Stravodimou, A Mougkou, ...
Oncology letters 20 (1), 441-447, 2020
Reversibility of renal impairment in patients with multiple myeloma treated with bortezomib-based regimens: identification of predictive factors
MA Dimopoulos, M Roussou, M Gavriatopoulou, F Zagouri, M Migkou, ...
Clinical Lymphoma and Myeloma 9 (4), 302-306, 2009
Low neutralizing antibody responses against SARS-CoV-2 in older patients with myeloma after the first BNT162b2 vaccine dose
E Terpos, IP Trougakos, M Gavriatopoulou, I Papassotiriou, AD Sklirou, ...
Blood, The Journal of the American Society of Hematology 137 (26), 3674-3676, 2021
Treatment of patients with relapsed/refractory multiple myeloma with lenalidomide and dexamethasone with or without bortezomib: prospective evaluation of the impact of …
MA Dimopoulos, E Kastritis, D Christoulas, M Migkou, M Gavriatopoulou, ...
Leukemia 24 (10), 1769-1778, 2010
Bortezomib, melphalan, and dexamethasone for light-chain amyloidosis
E Kastritis, X Leleu, B Arnulf, E Zamagni, MT Cibeira, F Kwok, P Mollee, ...
Journal of Clinical Oncology 38 (28), 3252-3260, 2020
Dexamethasone, rituximab, and cyclophosphamide as primary treatment of Waldenström macroglobulinemia: final analysis of a phase 2 study
E Kastritis, M Gavriatopoulou, MC Kyrtsonis, M Roussou, E Hadjiharissi, ...
Blood, The Journal of the American Society of Hematology 126 (11), 1392-1394, 2015
The neutralizing antibody response post COVID-19 vaccination in patients with myeloma is highly dependent on the type of anti-myeloma treatment
E Terpos, M Gavriatopoulou, I Ntanasis-Stathopoulos, A Briasoulis, ...
Blood Cancer Journal 11 (8), 138, 2021
A phase 1/2 study of lenalidomide with low-dose oral cyclophosphamide and low-dose dexamethasone (RdC) in AL amyloidosis
E Kastritis, E Terpos, M Roussou, M Gavriatopoulou, C Pamboukas, ...
Blood, The Journal of the American Society of Hematology 119 (23), 5384-5390, 2012
European myeloma network recommendations on diagnosis and management of patients with rare plasma cell dyscrasias
M Gavriatopoulou, P Musto, J Caers, G Merlini, E Kastritis, N van de Donk, ...
Leukemia 32 (9), 1883-1898, 2018
Reversibility of renal failure in newly diagnosed patients with multiple myeloma and the role of novel agents
M Roussou, E Kastritis, D Christoulas, M Migkou, M Gavriatopoulou, ...
Leukemia research 34 (10), 1395-1397, 2010
Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): updated outcomes from a …
SZ Usmani, H Quach, MV Mateos, O Landgren, X Leleu, D Siegel, ...
The Lancet Oncology 23 (1), 65-76, 2022
Diffuse pattern of bone marrow involvement on magnetic resonance imaging is associated with high risk cytogenetics and poor outcome in newly diagnosed, symptomatic patients …
LA Moulopoulos, MA Dimopoulos, E Kastritis, D Christoulas, ...
American journal of hematology 87 (9), 861-864, 2012
The system can't perform the operation now. Try again later.
Articles 1–20